Replimune’s BLA resubmission for RP1 in advanced melanoma has been accepted by the FDA, with an April 10, 2026, PDUFA date, resetting the regulatory clock after a July complete response letter. FDA Type A minutes indicate the ongoing IGNYTE-3 Phase 3 trial could potentially support approval, while the company signals readiness with a cash runway into late Q4 2026 and visible pre-commercial investment. The headline is simple: the first next-generation oncolytic HSV therapy paired with a PD-1 inhibitor is back on a defined path, with overall survival at the center of the confirmatory package.
The strategic question is whether regulators will greenlight a post–PD-1 option on the totality of evidence while IGNYTE-3 matures, or hold the line until survival data are persuasive. Melanoma in the post–checkpoint setting is increasingly competitive and operationally complex. The bar for durable benefit has risen since the arrival of TIL therapy, and a treatment that requires intratumoral injections and concomitant PD-1 therapy will face a different level of scrutiny than systemic agents. Acceptance of the resubmission suggests the issues were addressable, but the decisive factors are now clinical robustness and evidentiary clarity.
Clinically, the program leans on a mix of randomized and single-arm signals. IGNYTE-3, powered for overall survival versus the physician’s choice in patients who progressed on anti–PD-1 and anti–CTLA-4 or cannot take CTLA-4, is the linchpin. Recent ESMO readouts add texture: in acral melanoma, RP1 plus nivolumab produced a 44% objective response rate with nearly one-year median duration in a small cohort, and activity across multiple non-melanoma skin cancers, including anti–PD-1 naïve and failed disease. Upcoming SITC updates on biomarkers and retreatment aim to strengthen the mechanistic case that the virus reverses checkpoint resistance, data that could be pivotal for label language, adoption, and payer messaging.
For commercial teams, the calculus hinges on segmentation and operations. If approved, RP1 would enter the post–PD-1 melanoma space where TIL therapy offers high response at the cost of complex logistics, hospitalization, and substantial budgets. An in-office intratumoral therapy combined with an existing PD-1 could appeal to community and academic centers with injectable lesions and limited cell therapy capacity. Still, it introduces procedure workflow, biosafety handling, and site-of-care economics. Coverage dynamics will turn on whether the label mandates PD-1 co-administration, how payers view the incremental value over PD-1 rechallenge, and whether outcomes data translate into real-world durability.
Medical Affairs will carry an outsized load. Educating oncologists and dermatologic oncologists on patient selection, lesion accessibility, and retreatment protocols will be as important as explaining the mechanism. Real-world evidence programs should be ready on day one to document survival, resource utilization, and practice-level feasibility, particularly versus TIL and chemo. Signals in organ transplant recipients with cutaneous SCC point to a distinct niche where PD-1s are contraindicated, offering a potential early-practice beachhead if data mature.
Pipeline breadth provides optionality. RP2 heads into a registration-directed trial in metastatic uveal melanoma against ipilimumab plus nivolumab, and expansion into hepatocellular and biliary tract cancers broadens the platform’s relevance. The company is spending ahead of revenue, with rising SG&A reflecting field build. Yet, its cash runway through late 2026 buys one regulatory cycle and an initial launch—enough to prove commercial traction or force a strategic reset.
The next inflection arrives quickly: SITC biomarker readouts, FDA review cadence, and IGNYTE-3 enrollment progress will determine whether oncolytic immunotherapy can become a mainstream post–checkpoint modality. The crux for leaders across Commercial and Medical Affairs is whether Replimune can convert mechanism-rich, early signals into payer-validated, practice-friendly use before cell therapy and next-wave IO combinations lock down the refractory melanoma standard.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
